193. Prader-Willi syndrome Clinical trials / Disease details

Clinical trials : 113 / Drugs : 111 - (DrugBank : 26) / Drug target genes : 48 - Drug target pathways : 102

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05657860 (ClinicalTrials.gov)	December 17, 2020	12/12/2022	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome	A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome	Prader-Willi Syndrome;Aggression;Self-Injurious Behavior;Pathologic Processes;Behavioral Symptoms;Intellectual Disability;Neurobehavioral Manifestations;Neurologic Manifestations;Nervous System Diseases;Abnormalities, Multiple;Congenital Abnormalities;Chromosome Disorders;Genetic Diseases, Inborn;Obesity;Overnutrition;Nutrition Disorders;Antihypertensive Agents;Neurotransmitter Agents;Molecular Mechanisms of Pharmacological Action;Physiological Effects of Drugs;Skin-Picking	Drug: Guanfacine Extended Release;Other: Placebo	Maimonides Medical Center	NULL	Recruiting	6 Years	35 Years	All	33	Phase 4	United States
2	NCT04066088 (ClinicalTrials.gov)	December 1, 2019	21/8/2019	Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome	Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome	Prader-Willi Syndrome	Other: Placebo;Drug: Guanfacine extended release (GXR)	NYU Langone Health	Winthrop University Hospital	Withdrawn	6 Years	35 Years	All	0	Phase 4	United States